# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 21, "Diabetes Obes Metab .", "", "<http://ctro/data#Publication_44875> <http://ctro/data#hasJournal> \"Diabetes Obes Metab .\"."
1, PublicationYear, 22, 26, "2013", "", "<http://ctro/data#Publication_44875> <http://ctro/data#hasPublicationYear> \"2013\"."
42, Title, 107, 247, "Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P ) .", "", "<http://ctro/data#Publication_44875> <http://ctro/data#hasTitle> \"Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P ) .\"."
79549, Lixisenatide, 130, 142, "lixisenatide", "", 
13, Frequency, 143, 153, "once daily", "", 
20, Placebo, 161, 168, "placebo", "", 
26, Type2Diabetes, 172, 187, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_44882> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
39, Precondition, 172, 245, "type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P )", "", "<http://ctro/data#Population_44898> <http://ctro/data#hasPrecondition> \"type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P )\"."
30, Pioglitazone, 217, 229, "pioglitazone", "", 
43, Author, 248, 256, "Pinget M", "", "<http://ctro/data#Publication_44875> <http://ctro/data#hasAuthor> \"Pinget M\"."
44, Author, 265, 277, "Goldenberg R", "", "<http://ctro/data#Publication_44875> <http://ctro/data#hasAuthor> \"Goldenberg R\"."
45, Author, 280, 292, "Niemoeller E", "", "<http://ctro/data#Publication_44875> <http://ctro/data#hasAuthor> \"Niemoeller E\"."
46, Author, 295, 314, "Muehlen - Bartmer I", "", "<http://ctro/data#Publication_44875> <http://ctro/data#hasAuthor> \"Muehlen - Bartmer I\"."
47, Author, 317, 322, "Guo H", "", "<http://ctro/data#Publication_44875> <http://ctro/data#hasAuthor> \"Guo H\"."
48, Author, 325, 334, "Aronson R", "", "<http://ctro/data#Publication_44875> <http://ctro/data#hasAuthor> \"Aronson R\"."
49, France, 426, 432, "France", "", 
50, ObjectiveDescription, 442, 622, "To compare the efficacy and safety of once - daily prandial lixisenatide with placebo in type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin .", "", "<http://ctro/data#ClinicalTrial_44882> <http://ctro/data#hasObjectiveDescription> \"To compare the efficacy and safety of once - daily prandial lixisenatide with placebo in type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin .\"."
14, Frequency, 480, 492, "once - daily", "", 
79550, Lixisenatide, 502, 514, "lixisenatide", "", 
21, Placebo, 520, 527, "placebo", "", 
27, Type2Diabetes, 531, 555, "type 2 diabetes mellitus", "", 
40, Precondition, 531, 620, "type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin", "", "<http://ctro/data#Population_44898> <http://ctro/data#hasPrecondition> \"type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin\"."
28, Type2Diabetes, 558, 562, "T2DM", "", 
38, Pioglitazone, 594, 606, "pioglitazone", "", 
37, Metformin, 611, 620, "metformin", "", 
51, Randomized, 638, 648, "randomized", "", "<http://ctro/data#ClinicalTrial_44882> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
52, DoubleBlind, 651, 665, "double - blind", "", "<http://ctro/data#ClinicalTrial_44882> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
59, Duration, 683, 692, "24 - week", "", "<http://ctro/data#ClinicalTrial_44882> <http://ctro/data#hasCTduration> \"24 - week\"."
126, Duration, 721, 732, "≥ 52 - week", "", 
53, Randomized, 775, 785, "randomized", "", "<http://ctro/data#ClinicalTrial_44882> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
54, AllocationRatio, 786, 793, "2  :  1", "", "<http://ctro/data#AllocationRatio_44886> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#AllocationRatio>. <http://ctro/data#ClinicalTrial_44882> <http://ctro/data#hasAllocationRatio> <http://ctro/data#AllocationRatio_44886>."
79551, Lixisenatide, 805, 817, "lixisenatide", "", "<http://ctro/data#Medication_44936> <http://ctro/data#hasDrug> <http://ctro/data#Lixisenatide>."
55, DoseValue, 818, 820, "20", "", "<http://ctro/data#Medication_44936> <http://ctro/data#hasDoseValue> \"20\"."
130, Microgram, 821, 825, " µ g", "", "<http://ctro/data#Medication_44936> <http://ctro/data#hasDoseUnit> <http://ctro/data#Microgram>."
15, Frequency, 826, 836, "once daily", "", "<http://ctro/data#Intervention_44924> <http://ctro/data#hasFrequency> \"once daily\"."
22, Placebo, 840, 847, "placebo", "", "<http://ctro/data#Medication_44943> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
57, HbA1c, 885, 905, "glycated haemoglobin", "", 
58, HbA1c, 908, 913, "HbA1c", "", 
96, TimePoint, 919, 926, "week 24", "", 
60, NumberPatientsCT, 950, 953, "484", "", "<http://ctro/data#ClinicalTrial_44882> <http://ctro/data#hasNumberPatientsCT> \"484\"."
61, Randomized, 968, 978, "randomized", "", 
62, NumberPatientsArm, 981, 984, "323", "", "<http://ctro/data#Arm_44906> <http://ctro/data#hasNumberPatientsArm> \"323\"."
79552, Lixisenatide, 988, 1000, "lixisenatide", "", 
63, NumberPatientsArm, 1003, 1006, "161", "", "<http://ctro/data#Arm_44915> <http://ctro/data#hasNumberPatientsArm> \"161\"."
23, Placebo, 1010, 1017, "placebo", "", 
142, TimePoint, 1026, 1036, "24   weeks", "", "<http://ctro/data#Outcome_44994> <http://ctro/data#hasTimePoint> \"24   weeks\". <http://ctro/data#Outcome_45021> <http://ctro/data#hasTimePoint> \"24   weeks\"."
79554, Lixisenatide, 1039, 1051, "lixisenatide", "", 
16, Frequency, 1052, 1062, "once daily", "", 
65, HbA1c, 1086, 1091, "HbA1c", "", "<http://ctro/data#Endpoint_44989> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
152, DiffGroupAbsValue, 1094, 1102, "- 0 . 56", "", "<http://ctro/data#DiffBetweenGroups_45048> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 56\"."
67, Percentage, 1103, 1104, "%", "", "<http://ctro/data#Endpoint_44989> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
32, Placebo, 1110, 1117, "placebo", "", 
154, PvalueDiff, 1120, 1134, "p  <  0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_45048> <http://ctro/data#hasPvalueDiff> \"p  <  0 . 0001\"."
69, HbA1c_target, 1188, 1199, "HbA1c < 7 %", "", "<http://ctro/data#Endpoint_45057> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
161, Percentage, 1198, 1199, "%", "", 
33, Placebo, 1214, 1221, "placebo", "", 
70, PercentageAffected, 1224, 1230, "52 . 3", "", "<http://ctro/data#Outcome_45067> <http://ctro/data#hasPercentageAffected> \"52 . 3\"."
71, PercentageAffected, 1238, 1244, "26 . 4", "", "<http://ctro/data#Outcome_45094> <http://ctro/data#hasPercentageAffected> \"26 . 4\"."
72, PvalueDiff, 1264, 1278, "p  <  0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_45121> <http://ctro/data#hasPvalueDiff> \"p  <  0 . 0001\"."
73, FastingPlasmaGlucose, 1308, 1330, "fasting plasma glucose", "", "<http://ctro/data#Endpoint_45062> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
153, DiffGroupAbsValue, 1333, 1341, "- 0 . 84", "", "<http://ctro/data#DiffBetweenGroups_45184> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 84\"."
75, Millimoles_per_litre, 1344, 1352, "mmol / l", "", "<http://ctro/data#Endpoint_45062> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>."
34, Placebo, 1358, 1365, "placebo", "", 
155, PvalueDiff, 1368, 1382, "p  <  0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_45184> <http://ctro/data#hasPvalueDiff> \"p  <  0 . 0001\"."
65782, ObservedResult, 1397, 1413, "a small decrease", "", "<http://ctro/data#Outcome_45375> <http://ctro/data#hasObservedResult> \"a small decrease\"."
77, BodyWeight, 1417, 1428, "body weight", "", "<http://ctro/data#Endpoint_45370> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
79555, Lixisenatide, 1434, 1446, "lixisenatide", "", 
17, Frequency, 1447, 1457, "once daily", "", 
65788, ObservedResult, 1462, 1478, "a small increase", "", "<http://ctro/data#Outcome_45402> <http://ctro/data#hasObservedResult> \"a small increase\"."
35, Placebo, 1484, 1491, "placebo", "", 
65789, ObservedResult, 1499, 1561, "no statistically significant difference between the two groups", "", 
79556, Lixisenatide, 1574, 1586, "lixisenatide", "", 
18, Frequency, 1587, 1597, "once daily", "", 
171, EndPointDescription, 1648, 1683, "treatment - emergent adverse events", "", "<http://ctro/data#EndPointDescription_45194> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_45193> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_45194>."
80, EndPointDescription, 1686, 1691, "TEAEs", "", 
173, EndPointDescription, 1698, 1711, "serious TEAEs", "", "<http://ctro/data#EndPointDescription_45199> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_45198> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_45199>."
79562, Lixisenatide, 1729, 1741, "lixisenatide", "", 
82, PercentageAffected, 1744, 1750, "72 . 4", "", "<http://ctro/data#Outcome_45203> <http://ctro/data#hasPercentageAffected> \"72 . 4\"."
84, PercentageAffected, 1757, 1762, "2 . 5", "", "<http://ctro/data#Outcome_45257> <http://ctro/data#hasPercentageAffected> \"2 . 5\"."
24, Placebo, 1767, 1774, "placebo", "", 
83, PercentageAffected, 1777, 1783, "72 . 7", "", "<http://ctro/data#Outcome_45230> <http://ctro/data#hasPercentageAffected> \"72 . 7\"."
85, PercentageAffected, 1790, 1795, "1 . 9", "", "<http://ctro/data#Outcome_45284> <http://ctro/data#hasPercentageAffected> \"1 . 9\"."
86, SymptomaticHypoglycemia, 1802, 1827, "Symptomatic hypoglycaemia", "", "<http://ctro/data#Endpoint_45311> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#SymptomaticHypoglycemia>."
79559, Lixisenatide, 1876, 1888, "lixisenatide", "", 
87, PercentageAffected, 1889, 1894, "3 . 4", "", "<http://ctro/data#Outcome_45316> <http://ctro/data#hasPercentageAffected> \"3 . 4\"."
187, Percentage, 1895, 1896, "%", "", 
25, Placebo, 1901, 1908, "placebo", "", 
88, PercentageAffected, 1909, 1914, "1 . 2", "", "<http://ctro/data#Outcome_45343> <http://ctro/data#hasPercentageAffected> \"1 . 2\"."
188, Percentage, 1915, 1916, "%", "", 
89, ObservedResult, 1921, 1944, "with no severe episodes", "", "<http://ctro/data#Outcome_45316> <http://ctro/data#hasObservedResult> \"with no severe episodes\". <http://ctro/data#Outcome_45343> <http://ctro/data#hasObservedResult> \"with no severe episodes\"."
79557, Lixisenatide, 1947, 1959, "Lixisenatide", "", 
93, ConclusionComment, 2060, 2259, "Lixisenatide once daily significantly improved glycaemic control with a low risk of hypoglycaemia , and was well tolerated over 24   weeks and during the long - term , double - blind extension period", "", "<http://ctro/data#ClinicalTrial_44882> <http://ctro/data#hasConclusionComment> \"Lixisenatide once daily significantly improved glycaemic control with a low risk of hypoglycaemia , and was well tolerated over 24   weeks and during the long - term , double - blind extension period\"."
79560, Lixisenatide, 2060, 2072, "Lixisenatide", "", 
19, Frequency, 2073, 2083, "once daily", "", 
90, Hypoglycemia, 2144, 2157, "hypoglycaemia", "", 
91, Duration, 2188, 2198, "24   weeks", "", 
92, DoubleBlind, 2228, 2242, "double - blind", "", 
94, ConclusionComment, 2260, 2339, "in patients with T2DM insufficiently controlled on pioglitazone  ±  metformin .", "", "<http://ctro/data#ClinicalTrial_44882> <http://ctro/data#hasConclusionComment> \"in patients with T2DM insufficiently controlled on pioglitazone  ±  metformin .\"."
29, Type2Diabetes, 2277, 2281, "T2DM", "", 
31, Pioglitazone, 2311, 2323, "pioglitazone", "", 
36, Metformin, 2328, 2337, "metformin", "", 
95, PMID, 2408, 2416, "23627775", "", "<http://ctro/data#Publication_44875> <http://ctro/data#hasPMID> \"23627775\"."
